{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T23:04:00Z","timestamp":1789686240720,"version":"4.0.1"},"reference-count":46,"publisher":"The Endocrine Society","issue":"5","license":[{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020205","name":"Recordati AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Osilodrostat's clinical development program mostly enrolled Cushing disease patients. Data in nonpituitary Cushing syndrome (CS) patients are limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This work aims to evaluate osilodrostat effectiveness and safety in nonpituitary CS in real-world practice in France.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective, observational study (LINC 7; NCT05633953) was conducted in a multicenter institutional practice setting. Data for patients who initiated osilodrostat under the French Autorisation Temporaire d\u2019Utilisation program or, once approved, in routine clinical practice were extracted retrospectively for 36 months or less (2019-2022). Participants included 103 adult nonpituitary CS patients: ectopic adrenocorticotropin secretion (EAS), n = 53; adrenocortical carcinoma (ACC), n = 19; adrenal adenoma (AA), n = 17; and bilateral adrenal nodular disease (BND), n = 14. Forty-three patients remained on osilodrostat throughout the observation period. Median (minimum-maximum) osilodrostat exposure and baseline dose were 177 days (1-1178 days) and 5.0 mg\/day (1-60 mg\/day), respectively. The main outcome measure was the proportion with mean urinary free cortisol (mUFC) less than or equal to the upper limit of normal (ULN) at Wk 12 (modified intention-to-treat [mITT] population: all enrolled patients with \u226512 weeks' follow-up, excluding patients without Wk 12 mUFC for nonsafety reasons).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Osilodrostat was initiated and titrated based on investigator judgment. Cortisol decreased by Wk 4, remaining stable thereafter. Twenty-three of 52 patients (mITT, 44.2%; 95% CI, 30.5%-58.7%) had mUFC less than or equal to the ULN at Wk 12 (missing values reported as nonresponders). Forty-five of 52 had Wk 12 mUFC available; the proportions with mUFC less than or equal to the ULN by etiology were as follows: EAS, n = 12\/29 (41%); ACC, n = 4\/6; AA, n = 1\/3; and BND, n = 6\/7. The most common (\u226515%) treatment-emergent adverse events were adrenal insufficiency (28%) and hypokalemia (18%). Twenty-nine patients (EAS, n = 24; ACC, n = 5) died from adverse events (n = 1 assessed as osilodrostat related by investigator), most commonly neoplasm progression (n = 11).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Osilodrostat is a suitable treatment for endogenous CS of various nonpituitary etiologies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgaf633","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T12:45:21Z","timestamp":1763469921000},"page":"1287-1298","source":"Crossref","is-referenced-by-count":7,"title":["Real-World Osilodrostat Effectiveness and Safety in Nonpituitary Cushing Syndrome"],"prefix":"10.1210","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1231-3306","authenticated-orcid":false,"given":"Antoine","family":"Tabarin","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Diabetes and Nutrition, Centre de R\u00e9f\u00e9rence des Maladies Rares de la Surr\u00e9nale , CHU de Bordeaux, 33604 Pessac ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2551-3008","authenticated-orcid":false,"given":"J\u00e9r\u00f4me","family":"Bertherat","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Centre de R\u00e9f\u00e9rence des Maladies Rares de la Surr\u00e9nale, H\u00f4pital Cochin, AP-HP, and Universit\u00e9 Paris-Cit\u00e9 , 75014 Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9n\u00e9dicte","family":"Decoudier","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, CHU de Reims , 51100 Reims ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Lasolle","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, H\u00f4pital Louis Pradel, Hospices Civils de Lyon Bron Cedex, Lyon 1 University , 69500 Lyon ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6181-9648","authenticated-orcid":false,"given":"Herv\u00e9","family":"Lefebvre","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Rouen Normandie, INSERM, NorDiC UMR 1239, Department of Endocrinology, Diabetes and Metabolic Diseases, CHU Rouen , 76000 Rouen ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4579-4129","authenticated-orcid":false,"given":"Delphine","family":"Drui","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, CHU de Nantes , 44093 Nantes ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charly","family":"Vaillant","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, CH du Mans , 72037 Le Mans ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Morera","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, CHU de Caen , 14033 Caen ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Castinetti","sequence":"additional","affiliation":[{"name":"Aix-Marseille University, INSERM, MMG, Department of Endocrinology, La Conception Hospital, Assistance Publique Hopitaux de Marseille , 13005 Marseille ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0489-8914","authenticated-orcid":false,"given":"Justine","family":"Cristante","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Grenoble Alpes, Service d\u2019Endocrinologie, CHU Grenoble Alpes , 38043 Grenoble ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Chevalier","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, CHU de Nice , 06003 Nice ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Fodil-Cherif","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, CHU de Montpellier , 34295 Montpellier ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Young","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Assistance Publique H\u00f4pitaux de Paris, Bic\u00eatre Hospital, Paris Saclay University , 94270 Le Kremlin-Bic\u00eatre ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Piacentini","sequence":"additional","affiliation":[{"name":"Recordati SpA , 20148 Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wence","family":"Agbotounou","sequence":"additional","affiliation":[{"name":"Recordati AG , 4057 Basel ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Maldonado","sequence":"additional","affiliation":[{"name":"Recordati AG , 4057 Basel ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnd","family":"Mueller","sequence":"additional","affiliation":[{"name":"Recordati AG , 4057 Basel ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Scheyer","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes and Nutrition, CHRU de Nancy, H\u00f4pital Brabois et Universit\u00e9 de Lorraine , 54500 Vand\u0153uvre-l\u00e8s-Nancy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"issue":"10418","key":"2026042119564555500_dgaf633-B1","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/S0140-6736(23)01961-X","article-title":"Cushing's syndrome","volume":"402","author":"Gadelha","year":"2023","journal-title":"Lancet"},{"issue":"2","key":"2026042119564555500_dgaf633-B2","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1001\/jama.2023.11305","article-title":"Cushing syndrome: a review","volume":"330","author":"Reincke","year":"2023","journal-title":"JAMA"},{"key":"2026042119564555500_dgaf633-B3","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3389\/fmed.2018.00054","article-title":"The many faces of primary aldosteronism and cushing syndrome: a reflection of adrenocortical tumor heterogeneity","volume":"5","author":"Mete","year":"2018","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"2026042119564555500_dgaf633-B4","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1530\/EJE-19-0877","article-title":"Management of endocrine disease: Cushing's syndrome due to ectopic ACTH secretion: an expert operational opinion","volume":"182","author":"Young","year":"2020","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2026042119564555500_dgaf633-B5","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ecl.2018.02.003","article-title":"Adrenocortical carcinoma with hypercortisolism","volume":"47","author":"Puglisi","year":"2018","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"3","key":"2026042119564555500_dgaf633-B6","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1007\/s12020-018-1709-y","article-title":"Cushing's syndrome: comparison between Cushing's disease and adrenal Cushing's","volume":"62","author":"Hirsch","year":"2018","journal-title":"Endocrine"},{"issue":"4","key":"2026042119564555500_dgaf633-B7","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1530\/EJE-16-0809","article-title":"Prognostic factors in ectopic Cushing's syndrome due to neuroendocrine tumors: a multicenter study","volume":"176","author":"Davi","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2026042119564555500_dgaf633-B8","doi-asserted-by":"crossref","first-page":"e901","DOI":"10.1210\/clinem\/dgad453","article-title":"Long-term consequences of cushing syndrome: a systematic literature review","volume":"109","author":"Puglisi","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026042119564555500_dgaf633-B9","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1530\/EJE-13-0519","article-title":"Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center","volume":"169","author":"Ayala-Ramirez","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"2026042119564555500_dgaf633-B10","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1210\/jc.2015-1818","article-title":"Treatment of Cushing's syndrome: an Endocrine Society clinical practice guideline","volume":"100","author":"Nieman","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026042119564555500_dgaf633-B11","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S2213-8587(18)30155-4","article-title":"Advances in the medical treatment of Cushing's syndrome","volume":"7","author":"Feelders","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"2026042119564555500_dgaf633-B12","doi-asserted-by":"crossref","first-page":"L7","DOI":"10.1530\/EJE-20-0557","article-title":"Efficacy and tolerance of osilodrostat in patients with severe Cushing's syndrome due to non-pituitary cancers","volume":"183","author":"Haissaguerre","year":"2020","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2026042119564555500_dgaf633-B13","first-page":"267","article-title":"Adrenal Cushing's syndrome treated with preoperative osilodrostat and adrenalectomy","volume":"8","author":"Malik","year":"2022","journal-title":"AACE Clin Case Rep"},{"issue":"1","key":"2026042119564555500_dgaf633-B14","doi-asserted-by":"crossref","first-page":"43","DOI":"10.17925\/EE.2024.20.1.8","article-title":"Osilodrostat: a novel potent inhibitor of 11-beta-hydroxylase for the treatment of Cushing's syndrome","volume":"20","author":"Pivonello","year":"2024","journal-title":"touchREV Endocrinol"},{"issue":"9996","key":"2026042119564555500_dgaf633-B15","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0140-6736(14)61375-1","article-title":"Cushing's syndrome","volume":"386","author":"Lacroix","year":"2015","journal-title":"Lancet"},{"issue":"2","key":"2026042119564555500_dgaf633-B16","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s11102-015-0692-z","article-title":"Osilodrostat, a potent oral 11\u03b2-hydroxylase inhibitor: 22-week, prospective, phase II study in Cushing's disease","volume":"19","author":"Fleseriu","year":"2016","journal-title":"Pituitary"},{"issue":"6","key":"2026042119564555500_dgaf633-B17","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s11102-022-01280-6","article-title":"Long-term efficacy and safety of osilodrostat in Cushing's disease: final results from a phase II study with an optional extension phase (LINC 2)","volume":"25","author":"Fleseriu","year":"2022","journal-title":"Pituitary"},{"issue":"9","key":"2026042119564555500_dgaf633-B18","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S2213-8587(20)30240-0","article-title":"Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase","volume":"8","author":"Pivonello","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"2026042119564555500_dgaf633-B19","doi-asserted-by":"crossref","first-page":"e2882","DOI":"10.1210\/clinem\/dgac178","article-title":"Randomized trial of osilodrostat for the treatment of Cushing disease","volume":"107","author":"Gadelha","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2026042119564555500_dgaf633-B20","doi-asserted-by":"crossref","first-page":"1236465","DOI":"10.3389\/fendo.2023.1236465","article-title":"Long-term efficacy and safety of osilodrostat in patients with Cushing's disease: results from the LINC 4 study extension","volume":"14","author":"Gadelha","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"2026042119564555500_dgaf633-B21","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1530\/EJE-22-0317","article-title":"Long-term outcomes of osilodrostat in Cushing's disease: LINC 3 study extension","volume":"187","author":"Fleseriu","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"2026042119564555500_dgaf633-B22","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1507\/endocrj.EJ19-0617","article-title":"A multicenter, phase 2 study to evaluate the efficacy and safety of osilodrostat, a new 11\u03b2-hydroxylase inhibitor, in Japanese patients with endogenous Cushing's syndrome other than Cushing's disease","volume":"67","author":"Tanaka","year":"2020","journal-title":"Endocr J"},{"key":"2026042119564555500_dgaf633-B23","doi-asserted-by":"crossref","first-page":"903545","DOI":"10.3389\/fendo.2022.903545","article-title":"Metyrapone versus osilodrostat in the short-term therapy of endogenous Cushing's syndrome: results from a single center cohort study","volume":"13","author":"Detomas","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"2026042119564555500_dgaf633-B24","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1210\/clinem\/dgac691","article-title":"Efficacy and safety of osilodrostat in paraneoplastic cushing syndrome: a real-world multicenter study in France","volume":"108","author":"Dormoy","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026042119564555500_dgaf633-B25","doi-asserted-by":"crossref","first-page":"K1","DOI":"10.1530\/EJE-21-1008","article-title":"Efficacy and tolerance of osilodrostat in patients with Cushing's syndrome due to adrenocortical carcinomas","volume":"186","author":"Tabarin","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"2026042119564555500_dgaf633-B26","doi-asserted-by":"crossref","unstructured":"Tabarin A, Bertherat J, Decoudier B, et al \u00a0Supplementary appendix \u201cReal-World Osilodrostat Effectiveness and Safety in Nonpituitary Cushing Syndrome\u201d. Figshare. 2025. 10.6084\/m9.figshare.30667685","DOI":"10.1210\/clinem\/dgaf633"},{"issue":"3","key":"2026042119564555500_dgaf633-B27","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1530\/EJE-15-0968","article-title":"Prevalence and clinical features of the ectopic ACTH syndrome in patients with gastroenteropancreatic and thoracic neuroendocrine tumors","volume":"174","author":"Kamp","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"2026042119564555500_dgaf633-B28","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1210\/clinem\/dgab122","article-title":"Approach to the patient treated with steroidogenesis inhibitors","volume":"106","author":"Castinetti","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2026042119564555500_dgaf633-B29","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S2213-8587(16)00086-3","article-title":"Complications of Cushing's syndrome: state of the art","volume":"4","author":"Pivonello","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"2026042119564555500_dgaf633-B30","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1097\/HJH.0000000000003252","article-title":"Diagnosis and management of hypertension in patients with Cushing's syndrome: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension","volume":"40","author":"Fallo","year":"2022","journal-title":"J Hypertens"},{"issue":"Suppl. 1","key":"2026042119564555500_dgaf633-B31","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000314315","article-title":"Hypertension in Cushing's syndrome: from pathogenesis to treatment","volume":"92","author":"Cicala","year":"2010","journal-title":"Neuroendocrinology"},{"issue":"Suppl. 1","key":"2026042119564555500_dgaf633-B32","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1159\/000314316","article-title":"Management of diabetes mellitus in Cushing's syndrome","volume":"92","author":"Munir","year":"2010","journal-title":"Neuroendocrinology"},{"issue":"3","key":"2026042119564555500_dgaf633-B33","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s42000-019-00163-z","article-title":"Multiple hormone secretion may indicate worse prognosis in patients with ectopic Cushing's syndrome","volume":"19","author":"Lase","year":"2020","journal-title":"Hormones (Athens)"},{"issue":"5","key":"2026042119564555500_dgaf633-B34","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s40261-017-0497-0","article-title":"Drug interaction potential of osilodrostat (LCI699) based on its effect on the pharmacokinetics of probe drugs of cytochrome P450 enzymes in healthy adults","volume":"37","author":"Armani","year":"2017","journal-title":"Clin Drug Investig"},{"issue":"4","key":"2026042119564555500_dgaf633-B35","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1530\/EJE-14-0913","article-title":"Rapid control of severe neoplastic hypercortisolism with metyrapone and ketoconazole","volume":"172","author":"Corcuff","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"2026042119564555500_dgaf633-B36","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1177\/1060028020968808","article-title":"Osilodrostat: a novel steroidogenesis inhibitor to treat Cushing's cisease","volume":"55","author":"Dougherty","year":"2021","journal-title":"Ann Pharmacother"},{"issue":"1","key":"2026042119564555500_dgaf633-B37","doi-asserted-by":"crossref","first-page":"4666","DOI":"10.1038\/s41598-024-53913-4","article-title":"Clinical features and risk factors for postoperative recurrence in patients with Cushing's syndrome of different etiologies","volume":"14","author":"Cai","year":"2024","journal-title":"Sci Rep"},{"issue":"11","key":"2026042119564555500_dgaf633-B38","doi-asserted-by":"crossref","first-page":"e0242679","DOI":"10.1371\/journal.pone.0242679","article-title":"Ectopic ACTH syndrome of different origin\u2014diagnostic approach and clinical outcome. Experience of one clinical centre","volume":"15","author":"Palen-Tytko","year":"2020","journal-title":"PLoS One"},{"issue":"3","key":"2026042119564555500_dgaf633-B39","doi-asserted-by":"crossref","first-page":"258","DOI":"10.7861\/clinmedicine.17-3-258","article-title":"Adrenal insufficiency\u2014recognition and management","volume":"17","author":"Pazderska","year":"2017","journal-title":"Clin Med (Lond)"},{"key":"2026042119564555500_dgaf633-B40","doi-asserted-by":"crossref","first-page":"2042018819848218","DOI":"10.1177\/2042018819848218","article-title":"Adrenal crisis: prevention and management in adult patients","volume":"10","author":"Dineen","year":"2019","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"3","key":"2026042119564555500_dgaf633-B41","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/MED.0000000000000804","article-title":"Glucocorticoid withdrawal syndrome: what to expect and how to manage","volume":"30","author":"Theiler-Schwetz","year":"2023","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"5","key":"2026042119564555500_dgaf633-B42","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1210\/jc.2008-0125","article-title":"The diagnosis of Cushing's syndrome: an Endocrine Society clinical practice guideline","volume":"93","author":"Nieman","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026042119564555500_dgaf633-B43","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1210\/jc.2014-3766","article-title":"Urine free cortisol in the diagnosis of Cushing's syndrome: is it worth doing and, if so, how?","volume":"100","author":"Raff","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026042119564555500_dgaf633-B44","doi-asserted-by":"publisher","first-page":"bvae201","DOI":"10.1210\/jendso\/bvae201","article-title":"Improved clinical outcomes during long-term osilodrostat treatment of Cushing disease with normalization of late-night salivary cortisol and urinary free cortisol","volume":"9","author":"Newell-Price","year":"2024","journal-title":"J Endocr Soc"},{"issue":"11","key":"2026042119564555500_dgaf633-B45","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1007\/s40618-020-01246-0","article-title":"Long-acting pasireotide improves clinical signs and quality of life in Cushing's disease: results from a phase III study","volume":"43","author":"Lacroix","year":"2020","journal-title":"J Endocrinol Invest"},{"issue":"6","key":"2026042119564555500_dgaf633-B46","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1530\/EJE-22-0506","article-title":"Levoketoconazole treatment in endogenous Cushing's syndrome: extended evaluation of clinical, biochemical, and radiologic outcomes","volume":"187","author":"Fleseriu","year":"2022","journal-title":"Eur J Endocrinol"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgaf633\/65397655\/dgaf633.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/5\/1287\/65397655\/dgaf633.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/5\/1287\/65397655\/dgaf633.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T23:56:56Z","timestamp":1776815816000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/111\/5\/1287\/8328378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":46,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,11,19]]},"published-print":{"date-parts":[[2026,4,22]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgaf633","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2025,11,19]]}}}